John Collinge Selected Research

Acquired CJD

11/2017	Soluble Aβ aggregates can inhibit prion propagation.
4/2014	Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study.
8/2010	Heterozygosity at polymorphic codon 219 in variant creutzfeldt-jakob disease.
3/2008	Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice.
12/2007	Creutzfeldt-Jakob disease, prion protein gene codon 129VV, and a novel PrPSc type in a young British woman.
6/2006	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein.
12/2004	Human prion protein with valine 129 prevents expression of variant CJD phenotype.
12/2002	BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Collinge Research Topics

Disease

121	Prion Diseases (Transmissible Spongiform Encephalopathies) 10/2022 - 01/2002
48	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 01/2022 - 12/2002
47	Infections 12/2019 - 01/2003
32	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2022 - 12/2002
31	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 09/2009
26	Bovine Spongiform Encephalopathy (Mad Cow Disease) 12/2019 - 12/2002
23	Scrapie 12/2019 - 10/2002
15	Sporadic Creutzfeldt-Jakob Disease 01/2021 - 09/2006
12	Kuru 12/2019 - 06/2006
11	Disease Progression 01/2022 - 09/2006
11	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 12/2019 - 11/2006
9	Dementia (Dementias) 01/2022 - 02/2012
8	Frontotemporal Dementia (Semantic Dementia) 12/2019 - 02/2009
8	Acquired CJD 11/2017 - 12/2002
5	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 05/2022 - 11/2013
3	Chronic Wasting Disease 01/2022 - 10/2010
3	Brain Diseases (Brain Disorder) 11/2016 - 01/2016
3	Neuroblastoma 10/2014 - 02/2009
3	Proteostasis Deficiencies 01/2013 - 05/2010
3	Genetic Predisposition to Disease (Genetic Predisposition) 11/2008 - 07/2004
2	Amyloid Plaque 11/2021 - 11/2013
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 10/2020
2	Tauopathies 12/2019 - 11/2013
2	Gliosis 03/2012 - 10/2010
2	Sarcoma (Soft Tissue Sarcoma) 03/2012 - 07/2010
2	Zoonoses 01/2012 - 11/2007
1	Movement Disorders (Movement Disorder) 01/2022
1	Myoclonus (Nocturnal Myoclonus) 01/2022
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 10/2020
1	Pick Disease of the Brain (Pick's Disease) 01/2020
1	Mixed Dementias 01/2020
1	Amyloid angiopathy 12/2018
1	Chromosome 3-Linked Frontotemporal Dementia 11/2017
1	Atrophy 01/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2015
1	Glioma (Gliomas) 06/2015
1	Autoimmune Diseases of the Nervous System 06/2015

Drug/Important Bio-Agent (IBA)

103	PrionsIBA 01/2022 - 10/2002
93	Prion ProteinsIBA 10/2022 - 01/2002
39	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2006
23	Amyloid (Amyloid Fibrils)IBA 11/2021 - 03/2006
21	Protein Isoforms (Isoforms)IBA 12/2016 - 01/2002
16	Codon (Codons)IBA 01/2022 - 12/2002
9	Biomarkers (Surrogate Marker)IBA 12/2021 - 10/2010
8	Peptide Hydrolases (Proteases)FDA Link 01/2016 - 03/2006
7	Methionine (L-Methionine)FDA Link 01/2018 - 12/2002
6	AntibodiesIBA 01/2019 - 09/2004
6	UbiquitinIBA 03/2016 - 03/2008
5	Monoclonal AntibodiesIBA 01/2022 - 03/2003
5	ProgranulinsIBA 12/2018 - 03/2008
4	Valine (L-Valine)FDA Link 01/2016 - 12/2007
3	Apolipoproteins E (ApoE)IBA 12/2019 - 09/2015
3	Growth Hormone (Somatotropin)IBA 12/2018 - 09/2015
3	Proteasome Endopeptidase Complex (Proteasome)IBA 03/2016 - 11/2005
3	DNA-Binding Proteins (DNA Binding Protein)IBA 03/2012 - 07/2010
3	DNA (Deoxyribonucleic Acid)IBA 03/2012 - 09/2009
3	Quinacrine (Mepacrine)IBA 01/2012 - 12/2006
3	Biological ProductsIBA 01/2011 - 11/2008
2	BenzodiazepinesIBA 01/2022 - 03/2014
2	tau Proteins (tau Protein)IBA 10/2020 - 12/2018
2	ApolipoproteinsIBA 12/2019 - 11/2017
2	LipidsIBA 09/2019 - 01/2019
2	Glutamate Receptors (Glutamate Receptor)IBA 07/2017 - 03/2014
2	Detergents (Detergent)IBA 01/2016 - 03/2009
2	Leucine (L-Leucine)FDA Link 06/2015 - 06/2006
2	Protein AggregatesIBA 10/2014 - 10/2010
2	EpitopesIBA 08/2013 - 11/2006
2	Antimalarials (Antimalarial Agents)IBA 01/2012 - 04/2009
2	Complement System Proteins (Complement)IBA 01/2011 - 07/2010
2	Endopeptidase K (Proteinase K)IBA 12/2010 - 12/2008
2	MetalsIBA 08/2010 - 12/2007
2	Messenger RNA (mRNA)IBA 05/2010 - 02/2009
1	Amyloid beta-PeptidesIBA 05/2022
1	mouse Prnp proteinIBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	alpha-SynucleinIBA 01/2021
1	brazilinIBA 01/2021
1	SphingolipidsIBA 10/2020
1	Amyloidogenic ProteinsIBA 10/2020
1	SynucleinsIBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Apolipoprotein E4IBA 12/2019
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	Antisense OligonucleotidesIBA 12/2018
1	Peptides (Polypeptides)IBA 12/2017
1	Glutamic Acid (Glutamate)FDA Link 07/2017
1	Pharmaceutical PreparationsIBA 04/2016
1	Reducing AgentsIBA 01/2016
1	Mitochondrial DNA (mtDNA)IBA 10/2015
1	PolymersIBA 07/2015
1	anti-leucine-rich glioma-inactivated 1 autoantibodyIBA 06/2015
1	AntigensIBA 06/2015
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 06/2015
1	Glycine Receptors (Glycine Receptor)IBA 06/2015
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 06/2015

Therapy/Procedure

16	Therapeutics 10/2022 - 03/2003
2	Operative Surgical Procedures 12/2018 - 03/2005
2	Blood Transfusion (Blood Transfusions) 02/2011 - 12/2006
1	Transcutaneous Electric Nerve Stimulation (TENS) 01/2020
1	Enteral Nutrition (Feeding, Tube) 01/2019